Research programme: ocular therapeutics - Plex Pharmaceuticals

Drug Profile

Research programme: ocular therapeutics - Plex Pharmaceuticals

Latest Information Update: 15 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Plex Pharmaceuticals
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action HSP27 heat-shock protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cataracts

Most Recent Events

  • 15 Sep 2016 Research programme: ocular therapeutics - Plex Pharmaceuticals is available for licensing as of 15 Sep 2016. http://plexpharma.com/web/page.php?cid=5&pid=1
  • 10 Sep 2016 Early research in Cataracts in USA (unspecified route)
  • 07 Sep 2016 Plex Pharmaceuticals receives SBIR grant from NIH's National Eye Institute for fragment-based screening technology in Cataracts
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top